Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal By: TalkMarkets August 19, 2023 at 15:38 PM EDT Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a $3.5 million milestone. Read More >> Related Stocks: Arcutis Biotherapeutics Inc CytoMed Therapeutics Limited - Ordinary Shares Merck & Co One Bio Corp Summit Therapeu ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal By: TalkMarkets August 19, 2023 at 15:38 PM EDT Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a $3.5 million milestone. Read More >> Related Stocks: Arcutis Biotherapeutics Inc CytoMed Therapeutics Limited - Ordinary Shares Merck & Co One Bio Corp Summit Therapeu ADR